Novagali eye Treatment for Vernal Keratoconjunctivitis (VKC) Successful in Phase III Trial novagali眼治療春季角結膜炎( vkc )成功地在第三階段試驗
Tuesday, April 10th, 2007 週二, 2007年4月10日Israeli-French drug development company Novagali SA, which was founded on the basis of research conducted by Prof. Simon Benita of the Hebrew University of Jerusalem, has successfully completed European Medicines Agency (EMEA) Phase III clinical trials of its eye treatment for Vernal Keratoconjunctivitis (VKC)..以色列-法國藥物開發公司novagali SA服務,這是基礎上建立的進行的研究教授西蒙貝妮塔的耶路撒冷希伯來大學,成功地完成了歐洲藥品管理局( EMEA )來第三階段的臨床實驗,其眼治療春季角結膜炎( vkc ) ..
































